| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_511f251da888aa746ff2cb5e15737fd6 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-46 |
| filingDate |
2020-10-26^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_47373cfa217ae79647e295315a0b95eb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_db84fdbae4316a9e97fb46397d3e8ccd |
| publicationDate |
2021-06-03^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021108051-A2 |
| titleOfInvention |
Atropine-scopolamine with enhanced stability |
| abstract |
This disclosure relates to stable formulations of atropine and scopolamine for use as a medical countermeasure to combat organophosphate nerve agent threats. The formulations exploit complementary pharmacological profiles for optimal receptor blockade and anticholinergic activity within the peripheral and central nervous system. The formulations are suitable for intramuscular injection, and have stability that exceeds two years in stressed conditions. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115356413-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021108051-A3 |
| priorityDate |
2019-10-25^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |